Robbins R C, Kown M H, Portner P M, Oyer P E
Department of Cardiothoracic Surgery, Falk Cardiovascular Research Center, Stanford University School of Medicine, California 94305-5407, USA.
Ann Thorac Surg. 2001 Mar;71(3 Suppl):S162-5; discussion S183-4. doi: 10.1016/s0003-4975(00)02643-6.
The Novacor Left Ventricular Assist System (LVAS) (Novacor Corp, Oakland, CA) was initially console-based and has been available since 1993 in a wearable configuration. It has been successfully used for the past 16 years as a bridge to cardiac transplantation in patients with end-stage congestive heart failure. The Stanford experience represents 53 patients (48 male, 5 female) with a mean age of 44 +/- 13 years (16 to 62) and a mean support time of 56 +/- 76 days (1 to 374). Complications with LVAS use consisted predominantly of bleeding (43%), infection, (30%), and embolic cerebrovascular events (24.5%). Sixty-six percent of the supported patients were successfully bridged to cardiac transplantation. In animal studies, 4 sheep had the totally implantable configuration in place for a cumulative duration of 1 year with 1 animal supported for 260 days. The next generation Novacor LVAS will be small, quiet, and fully implantable without the need for volume compensation. It will also provide physiologic pulsatile flow and will be fail-safe.
诺瓦科尔左心室辅助系统（LVAS）（诺瓦科尔公司，加利福尼亚州奥克兰）最初是基于控制台的，自1993年以来一直有可穿戴配置。在过去16年中，它已成功用于终末期充血性心力衰竭患者作为心脏移植的桥梁。斯坦福大学的经验涵盖53例患者（48例男性，5例女性），平均年龄44±13岁（16至62岁），平均支持时间56±76天（1至374天）。使用LVAS的并发症主要包括出血（43%）、感染（30%）和栓塞性脑血管事件（24.5%）。66%的受支持患者成功过渡到心脏移植。在动物研究中，4只绵羊植入了完全可植入的配置，累计时长1年，其中1只动物得到了260天的支持。下一代诺瓦科尔LVAS将体积小、噪音小，且完全可植入，无需进行容量补偿。它还将提供生理性搏动血流，并且具备故障安全功能。
